Clinical Trial Detail

NCT ID NCT02337829
Title ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

CLL/SLL

Therapies

Acalabrutinib

Age Groups: adult

No variant requirements are available.